Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)
Arthritis & Rheumatism2004Vol. 50(4), pp. 1270–1276
Citations Over TimeTop 1% of 2004 papers
Xavier Mariette, Philippe Ravaud, Serge Steinfeld, Gabriel Baron, Joëlle Goetz, É. Hachulla, Bernard Combe, Xavier Puéchal, Yvon Pennec, B Sauvezie, Aleth Perdriger, Gilles Hayem, Anne Janin, Jean Sibilia
Abstract
This randomized, double-blind, placebo-controlled study of an anti-TNF agent did not show any evidence of efficacy of infliximab in primary SS.
Related Papers
- → Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease(2011)111 cited
- Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.(2006)
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- → Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?(2009)22 cited
- [Management of failure of infliximab in inflammatory bowel disease].(2011)